Genetic Diagnostic Centre

gdc-egypt.com

Genetic Diagnostic Center is a leading Egyptian medical center dedicated to delivering innovative medical genetics services for patients and other healthcare providers. In GDC, we combine 50 years of experience with the latest cutting-edge technologies to offer a quality driven performance in Cytogenetics, Molecular Genetics, Hematopathology, Flow Cytometry and Immunohistochemistry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

THE LYNX GROUP ACQUIRES UPSTREAM PARTNERS TO CREATE A DYNAMIC DIVISION CATERING DIRECTLY TO THE PHARMACEUTICAL AND BIOTECH SPACE

The Lynx Group | August 14, 2020

news image

The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...

Read More

CELL AND GENE THERAPY

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

news image

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More

CELL AND GENE THERAPY

TUMORGEN AND PHENOVISTA CAPTURE THE SEEDS THAT DRIVE CANCER METASTASIS

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

news image

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

Read More

CELL AND GENE THERAPY

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

news image

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More
news image

THE LYNX GROUP ACQUIRES UPSTREAM PARTNERS TO CREATE A DYNAMIC DIVISION CATERING DIRECTLY TO THE PHARMACEUTICAL AND BIOTECH SPACE

The Lynx Group | August 14, 2020

The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...

Read More
news image

CELL AND GENE THERAPY

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More
news image

CELL AND GENE THERAPY

TUMORGEN AND PHENOVISTA CAPTURE THE SEEDS THAT DRIVE CANCER METASTASIS

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

Read More
news image

CELL AND GENE THERAPY

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More